Oral Therapies for Multiple Sclerosis in Recent Years

The injectable immunomodulators interferon and glatiramer acetate have dominated the multiple sclerosis (MS) market for the past two decades. Recently, new oral drugs have been approved by the US Food and Drug Administration for the treatment of MS. In this review, we discuss four new oral therapies for MS:fingolimod, laquinimod, BG?12, and teriflunomide, including their mechanisms of action, clinical trial efficacy, and safety profile, as well as the implications for clinical practice.